BioNTech, the German company that gained global recognition during the COVID-19 pandemic for its mRNA vaccine, has announced that it is stopping vaccine production in Germany and transferring the process to its U.S. partner Pfizer.
The company will manufacture its final doses this year before fully withdrawing from COVID-19 vaccine production, according to Deutsche Welle.
In the future, BioNTech plans to shift its focus toward scientific research, particularly treatments for other diseases such as cancer, moving away from large-scale vaccine production and toward the development of innovative therapies.
